This $400,000 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports research by General Biophysics LLC to evaluate the use of inhaled xenon gas as a novel treatment for opioid withdrawal symptoms. The key activities include pre-clinical target engagement studies to analyze the effects of xenon inhalation on inflammatory markers in brain tissue and blood samples from healthy adults and patients with opioid use disorder. This work will inform the design of a future clinical trial to assess the potential of xenon gas to blunt opioid withdrawal and reduce morbidity and mortality among those with opioid use disorder who do not respond to existing treatments. The project is a collaboration between General Biophysics, McLean Hospital, and Brigham & Women's Hospital, leveraging their expertise in opioid use disorder research and development of xenon-based therapeutics.
Generated 3/4/25, 5:52 AM